PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11054644-0	2000	Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult mice.	pegvisomant	67-76	growth hormone	Mus musculus	31-45	
16541323-2	2006	In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth.	pegvisomant	61-72	growth hormone	Mus musculus	46-48	
16541323-5	2006	This effect of pegvisomant was mediated by a complete inhibition of both GH and IGF-IR-mediated signaling within the gland.	pegvisomant	15-26	growth hormone	Mus musculus	73-75	
24035867-5	2014	Since the GH/IGF-1 axis has been implicated in the progression of several types of cancers, many have suggested the use of pegvisomant as an anti-cancer therapeutic.	pegvisomant	123-134	growth hormone	Mus musculus	10-12